---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-23-000119"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:20:28.637111+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Denali Q2 net income $183M on Biogen opt-in; discontinues DNL919 in Alzheimer's

## Summary
- Net income $183.4M (Q2 2022: net loss $58.8M) on $294.1M collaboration revenue from Biogen's ATV:Abeta option.
- Discontinued DNL919 (ATV:TREM2) in Alzheimer's due to narrow therapeutic window and evolving treatment landscape.
- Biogen exercised option to license ATV-amyloid-beta program; will handle development and commercialization.
- Revised BIIB122 (LRRK2) program: focus on LUMA study in Parkinson's; LIGHTHOUSE discontinued, no safety issues.
- Cash and marketable securities $1.19B; DNL310 showed ~40-64% NfL reduction in MPS II, IND cleared for DNL126.

## SEC filing metadata
- accession: 0001714899-23-000119
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000119/0001714899-23-000119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000119/dnli-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-23-000119
- JSON: https://secwatch.observer/filing/0001714899-23-000119.json
- Plain text: https://secwatch.observer/filing/0001714899-23-000119.txt

## Key facts
- Earnings Releases
  Denali Therapeutics Inc. reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 8, 2023, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000119/0001714899-23-000119-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.